Ascendis Pharma A/S
ASND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $539 | $494 | $518 | $560 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $135 | $110 | $67 | $166 |
| Inventory | $302 | $303 | $293 | $296 |
| Other Curr. Assets | $42 | $45 | $44 | $39 |
| Total Curr. Assets | $1,018 | $953 | $921 | $1,061 |
| Property Plant & Equip (Net) | $102 | $94 | $92 | $99 |
| Goodwill | $0 | $0 | $0 | $3 |
| Intangibles | $4 | $4 | $4 | $1 |
| Long-Term Investments | $28 | $35 | $41 | $14 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $3 | $3 | $3 | $2 |
| Total NC Assets | $137 | $135 | $140 | $119 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $1,155 | $1,088 | $1,061 | $1,179 |
| Liabilities | – | – | – | – |
| Payables | $79 | $94 | $84 | $96 |
| Short-Term Debt | $482 | $462 | $490 | $492 |
| Tax Payable | $0 | $0 | $2 | $1 |
| Deferred Revenue | $4 | $2 | $1 | $1 |
| Other Curr. Liab. | $421 | $377 | $308 | $318 |
| Total Curr. Liab. | $986 | $935 | $886 | $908 |
| LT Debt | $331 | $330 | $357 | $365 |
| Deferred Rev, NC | $1 | $1 | $1 | $5 |
| Deferred Tax Liab, NC | $10 | $10 | $8 | $7 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $342 | $340 | $366 | $377 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $1,329 | $1,275 | $1,251 | $1,285 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $8 | $8 | $8 | $8 |
| Retained Earnings | -$2,705 | -$2,666 | -$2,658 | -$2,560 |
| AOCI | -$1 | $0 | $2 | $2 |
| Other Equity | $2,524 | $2,470 | $2,458 | $2,444 |
| Total Equity | -$174 | -$188 | -$190 | -$106 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $1,155 | $1,088 | $1,061 | $1,179 |
| Net Debt | $275 | $298 | $329 | $297 |